Remdesivir reduces mortality in hospitalized COVID-19 patients, 3 real-world studies show


Remdesivir, the antiviral drug Gilead sells under the brand name Veklury, reduced mortality rates in hospitalized COVID-19 patients and increased their likelihood of being discharged by day 28 after a five-day regimen, Gilead said June 21.

The announcement is based on three retrospective studies examining the real-world treatment of 98,654 hospitalized COVID-19 patients.

In two of the studies, remdesivir reduced patients' mortality risk by 54 percent and 23 percent.

Remdesivir became the first FDA-approved COVID-19 treatment in October.


© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars